PubMed Health⌕ Search

PubMed · 6698657

Acarbose in reactive hypoglycemia: a double-blind study.

Abstract

This study investigates the effect of Acarbose, a complex oligosaccharide of microbial origin with glucosidase-inhibiting properties in alimentary hypoglycemia secondary to rapid gastric emptying and in reactive hypoglycemia either isolated or associated with impaired glucose tolerance. Twenty-four patients complaining of symptoms suggesting hypoglycemia which occurred after meals and who showed blood glucose values of 2.5 mmol/l (45 mg/dl) or below on one or more occasions during a 5-h oral glucose tolerance test were selected and divided into three groups. Group I comprized seven patients with demonstrated rapid gastric emptying; group II comprized eight patients with impaired glucose tolerance, whereas the nine patients of group III were considered to present with "isolated reactive hypoglycemia" since they had a normal glucose tolerance and did not have either glycosuria or gastroduodenal pathology. All patients were submitted to two oral 75-g sucrose tolerance tests. Acarbose (100 mg) or placebo was ingested with the first drought of the sucrose solution administered in a randomized order. The investigation was performed in a double-blind manner. In all three groups Acarbose significantly reduced the magnitude of post-sucrose reactive hypoglycemia. The blood glucose nadir also occurred later, but this effect was statistically significant in group II only. In patients of groups II and III, such improvement of the glucose nadirs was preceded by a significant reduction of the post-sucrose glycemic peak. In all three groups, the insulin response to oral sucrose was reduced by Acarbose. Another consistent finding was the lack of sucrose-induced glucagon suppression when Acarbose was given. These data suggest that Acarbose might be a useful adjunct to the management of functional hypoglycemia.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Gérard, A S Luyckx, P J Lefèbvre. 1984. Acarbose in reactive hypoglycemia: a double-blind study.. https://pubmed.ncbi.nlm.nih.gov/6698657/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol) effectively inhibit alpha-glucosidase.

The standardized maritime pine bark extract (Pycnogenol) was reported to exert clinical anti-diabetic effects after peroral intake. However, an increased insulin secretion was not observed after administration of the extract to patients. Our aim was to elucidate whether the described clinical effects of Pycnogenol are related to inhibition of alpha-glucosidase. Therefore, we analyzed the inhibitory activity of Pycnogenol, green tea extract and acarbose towards alpha-glucosidase. Furthermore, we explored different fractions of Pycnogenol containing compounds of diverse molecular masses from polyphenolic monomers, dimers and higher oligomers to uncover which components exhibited the most pronounced inhibitory activity. We found that Pycnogenol exhibited the most potent inhibition (IC(50) about 5 microg/mL) on alpha-glucosidase compared to green tea extract (IC(50) about 20 microg/mL) and acarbose (IC(50) about 1mg/mL). The inhibitory action of Pycnogenol was stronger in extract fractions containing higher procyanidin oligomers. The results obtained assign a novel, local effect to oligomeric procyanidins and contribute to the explanation of glucose-lowering effects of Pycnogenol observed in clinical trials with diabetic patients.

Acarbose↗

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.

BACKGROUND: Alpha-glucosidase inhibitors (AGIs) reduce blood glucose levels and may thus prevent type 2 diabetes and cardiovascular disease in patients with impaired glucose tolerance. These possible effects, and the effects on quality of life, plasma lipids and body weight, have never been investigated in a systematic literature review and meta-analysis. OBJECTIVES: To assess the effects of alpha-glucosidase inhibitors in patients with impaired glucose tolerance (IGT) or impaired fasting blood glucose (IFBG), or both. SEARCH STRATEGY: We searched The Cochrane Library (Clinical Trials database, formerly known as CENTRAL), PUBMED, EMBASE, Web of Science, LILACS, databases of ongoing trials, reference lists of relevant reviews, and we contacted experts and manufacturers. Date of last search was February 2006. SELECTION CRITERIA: Randomised controlled trials of at least one-year duration in patients with IGT or IFBG, or both, comparing AGI monotherapy with any other intervention. DATA COLLECTION AND ANALYSIS: Two reviewers read all abstracts, assessed quality and extracted data independently. Discrepancies were resolved by consensus or by the judgement of a third reviewer. MAIN RESULTS: We included five trials (2360 participants), all investigating acarbose, that included patients with IGT or patients 'at increased risk for diabetes' (n = 1). Study duration was one, three (n = 2), five and six years. One study was at low risk of bias and four studies at high risk of bias. Except for the outcome incidence of type 2 diabetes in acarbose versus no treatment (two studies), meta-analyses were not possible. Data from the study at low risk of bias suggests that acarbose decreases the occurrence of type 2 diabetes (NNT = 10), cardiovascular events (NNT = 50, based on 47 events, study not initially powered for this outcome), post-load blood glucose (-0.6 mmol/L, 95% CI -1.0 to -0.3) and body mass index (0.3 kg/m(2), 95% CI -0.1 to -0.5). No statistically significant effects were observed on mortality, other morbidity, glycated haemoglobin, fasting blood glucose, lipids and blood pressure. The effects on the incidence of type 2 diabetes were confirmed in two studies at high risk of bias (OR 0.2, 95% CI 0.1 to 0.6). Adverse effects were mostly of gastro-intestinal origin (OR 3.5, 95% CI 2.7 to 4.4). AUTHORS' CONCLUSIONS: There is evidence that acarbose reduces the incidence of type 2 diabetes in patients with IGT. However, it is unclear whether this should be seen as prevention, delay or masking of diabetes. Acarbose may prevent the occurrence of cardiovascular events, but this finding needs to be confirmed in more studies.

Acarbose↗